Compare AISP & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AISP | RCEL |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.1M | 102.5M |
| IPO Year | N/A | N/A |
| Metric | AISP | RCEL |
|---|---|---|
| Price | $2.79 | $4.06 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.17 |
| AVG Volume (30 Days) | ★ 1.1M | 240.3K |
| Earning Date | 03-02-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $12,033,886.00 | ★ $72,401,000.00 |
| Revenue This Year | $34.52 | $13.61 |
| Revenue Next Year | $59.54 | $19.61 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 20.59 |
| 52 Week Low | $2.69 | $3.22 |
| 52 Week High | $7.20 | $11.25 |
| Indicator | AISP | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 38.29 | 53.27 |
| Support Level | $2.69 | $4.21 |
| Resistance Level | $3.30 | $4.56 |
| Average True Range (ATR) | 0.34 | 0.28 |
| MACD | -0.08 | 0.01 |
| Stochastic Oscillator | 5.86 | 56.96 |
Airship AI Holdings Inc is a robust AI-driven data management platform that solves complex data challenges for large institutions operating in dynamic and mission-critical environments with rapidly increasing volumes of data being ingested from a similarly rapidly growing number of data sources. Its primary offerings include Outpost AI, Acropolis, and Airship Command. Its offerings allow customers to manage their data across the full data lifecycle, when and where need it, using a secure permission-based architecture.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.